UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10 22, 2025 ~~(October 6, 2025)~~

AIMFINITY INVESTMENT CORP. I

(Exact name of registrant as specified in its charter)

Cayman Islands	001-41361	N/A
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification Number)

221 W 9th St, PMB 235
Wilmington, Delaware 19801

(Address of principal executive offices)

(425) 365-2933

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol	Name of each exchange on which registered
Units, consisting of one New Unit and one Class 1 redeemable warrant, each exercisable for one Class A ordinary share at an exercise price of $11.50	AIMUF	OTC Market Group, Inc.
Units, consisting of one Class A ordinary share, $0.0001 par value, one Class 1 redeemable warrant and one-half of one Class 2 redeemable warrant	AIMAU	The Nasdaq Stock Market LLC
New Units, consisting of one Class A ordinary share and one-half of one Class 2 redeemable warrant, each full exercisable for one Class A ordinary share at an exercise price of $11.50	AIMTF	OTC Market Group, Inc.
Class A ordinary shares, $0.0001 par value	AIMA	The Nasdaq Stock Market LLC
Class 1 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50	~~AIMWF~~AIMAW	~~OTC~~The ~~Market~~Nasdaq ~~Group,~~Stock ~~Inc.~~Market LLC
Class 2 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50	AIMAW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~AMENDMENT ~~1.01~~AND ~~Entry~~SUPPLEMENT ~~into~~TO aTHE ~~Material~~PROXY ~~Definitive Agreement~~STATEMENT

AsThe ~~previously~~following ~~disclosed~~disclosures ~~by Aimfinity Investment Corp. I (“AIMA” or the “Company”)~~ in ~~its~~this Current Report on Form 8-K supplement, and ~~filed~~should onbe ~~October~~read ~~16,~~in ~~2023,~~conjunction onwith ~~October~~the ~~13,~~disclosures ~~2023,~~contained in the Company’s ~~entered~~definitive ~~into that~~proxy ~~certain~~statement ~~Agreement and Plan of Merger~~ (as the same may be amended, ~~supplemented~~ or ~~otherwise modified from time to time~~supplemented, the “~~Merger Agreement~~Proxy Statement”), filed with ~~Docter~~the ~~Inc.,~~Securities aand ~~Delaware~~Exchange ~~corporation~~Commission (the “~~Docter~~SEC”), on ~~Aimfinity~~October ~~Investment~~14, ~~Merger Sub I~~2025, ain ~~Cayman~~connection ~~Islands exempted~~with ~~company~~the ~~and~~extraordinary ~~wholly-owned~~general ~~subsidiary~~meeting of ~~AIMA~~shareholders ~~(“Purchaser”),~~in ~~and~~lieu ~~Aimfinity~~of ~~Investment~~an ~~Merger~~annual ~~Sub~~general ~~II,~~meeting ~~Inc.,~~on ~~a Delaware~~October ~~corporation~~27, ~~and~~2025 ~~wholly-owned subsidiary of Purchaser~~ (the “~~Merger~~Extraordinary ~~Sub~~Meeting”),. ~~pursuant~~To tothe ~~which~~extent ~~AIMA~~the ~~will~~information ~~complete~~set aforth ~~business~~herein ~~combination~~differs from or updates information ~~(the~~contained ~~“Business~~in ~~Combination”)~~the ~~with~~Proxy ~~Docter~~Statement, ~~that~~the ~~involves~~information aset ~~reincorporation~~forth ~~merger~~herein ~~and~~shall ansupersede ~~acquisition~~or ~~merger.~~supplement ~~The~~the ~~Purchaser~~information ~~shall survive~~in the ~~Business~~Proxy ~~Combination~~Statement, which ~~and~~shall be ~~referred~~read toin asits ~~“PubCo”~~entirety. ~~after~~All other information in the ~~Business~~Proxy ~~Combination~~Statement remains unchanged.

AsThe ~~previously~~purpose ~~disclosed, on May 27, 2025, PubCo, Mr. I-Fa Chang, CEO and Chairman~~ of ~~AIMA (~~the ~~“Seller”),~~supplemental ~~and~~disclosures ~~Inkrock~~is ~~Holding~~to ~~Limited,~~provide ~~a British Virgin Islands company (“Inkrock”,~~information ~~together~~about ~~with PubCo and Seller,~~ the ~~“Parties”),~~adjournment ~~entered~~of ~~into a securities purchase agreement (~~the ~~“May~~Extraordinary 27Meeting. ~~Agreement”) pursuant~~Terms toused ~~which the Seller agreed to transfer (the “Transfer”) all the securities it holds in Inkrock to PubCo~~herein, inunless ~~exchange for~~otherwise ~~the issuance (the “Issuance”) of 687~~defined,~~054~~ ~~ordinary~~have ~~shares, par value $0.0001 per share, of~~ the ~~Company~~meanings ~~(the~~set ~~“Consideration Shares”)~~forth onin the ~~date of the agreement~~Proxy Statement. ~~As of the date hereof, the Transfer has not been effected.~~

~~For~~Amendment ~~accounting purposes, and in light of the fact that the transactions provided in the May 27 Agreement have not been fully consummated, on October 6, 2025, the Parties agreed~~ to ~~enter into a termination agreement to unwind~~ the ~~transactions~~Questions ~~provided in the May 27 Agreement~~ and toAnswers ~~discharge~~About ~~each Party from further obligations under~~ the ~~May~~Extraordinary ~~27 Agreement.~~Meeting

In ~~its~~response ~~place,~~to ~~the~~inquiries ~~Parties~~from ~~entered~~shareholders ~~into~~of ~~a new securities purchase agreement (~~the ~~“New Agreement”) on October 7~~Company, ~~2025, pursuant to which,~~ the ~~Seller agreed to Transfer all the securities it holds in~~following ~~Inkrock~~question-and-answer tois ~~PubCo,~~added ~~in exchange for the Issuance of the Consideration Shares~~ to the ~~Seller,~~Questions ~~with~~and ~~both~~Answers ~~the~~About ~~Transfer and~~ the ~~Issuance~~Extraordinary ~~taking place~~Meeting ~~simultaneously~~to ~~with~~provide ~~the~~clarification ~~closing~~for of the ~~Business Combination.~~shareholders:

~~Copies~~Q: ofWhat ~~the~~if ~~Termination~~you ~~Agreement~~reverse ~~and~~or ~~the~~withdraw ~~New~~your ~~Agreement~~previous ~~are~~redemption ~~filed~~request asin ~~Exhibits~~connection ~~10.1~~with ~~and~~the ~~10.2,~~Docter ~~respectively,~~Business toCombination ~~this~~in ~~Current~~order ~~Report~~to onredeem ~~Form~~your ~~8-K~~shares ~~and~~in ~~are~~connection ~~incorporated~~with ~~herein~~this byExtraordinary ~~reference.~~Meeting ~~The~~and ~~disclosures~~we ~~set~~complete ~~forth~~the inDocter ~~this~~Business ~~Item~~Combination ~~2.03~~prior ~~are intended~~ to bethe ~~summaries~~Extraordinary ~~only~~Meeting ~~and~~or ~~are~~we ~~qualified~~do innot ~~their~~hold ~~entirety by reference to~~ the ~~respective~~Extraordinary ~~exhibit.~~Meeting?

~~Item~~A: ~~3.02.~~As ~~Unregistered~~provided ~~Sales~~elsewhere ofin ~~Equity~~the ~~Securities~~proxy statement, if you have elected to redeem your shares in connection with the Business Combination EGM previously but wish to redeem your shares now in connection with the Extraordinary Meeting/Charter Amendment Proposal, you need to reverse or withdraw your redemption request previously submitted to the Company, and elect to redeem your shares in connection with this Extraordinary Meeting.

~~The~~However, ~~disclosure~~there ~~set~~is ~~forth~~no ~~above~~assurance inthat ~~Item~~we ~~1.01~~will ofhold ~~this~~the ~~Current~~Extraordinary ~~Report~~Meeting onand ~~Form~~implement ~~8-K~~the isProposals, ~~incorporated~~if, byfor ~~reference~~example, ~~herein~~we consummate the Docter Business Combination prior to the Extraordinary Meeting.

1 Therefore, depending on the timing and sequence of the events:

~~IMPORTANT~~· ~~NOTICES~~If we consummate the Docter Business Combination prior to this Extraordinary Meeting, the Extraordinary Meeting and the Proposals will not be implemented:

Aso ~~disclosed~~Any ~~previously~~redemption onrequest ~~the~~originally ~~Current~~submitted ~~Report~~in onconnection ~~Form~~with ~~8-K~~the ~~filed~~Docter ~~with the~~Business ~~Securities~~Combination ~~and~~will ~~Exchange~~automatically ~~Commission~~be (redeemed in connection with the ~~“SEC”)~~consummation onof ~~October~~the ~~16,~~Docter ~~2023,~~Business onCombination. ~~October~~Even ~~13,~~if ~~2023,~~you ~~AIMA~~have ~~entered~~reversed ~~into~~or ~~that~~withdrawn ~~certain Merger~~such ~~Agreement,~~request ~~with~~in ~~Docter,~~order ~~Purchaser,~~to ~~and~~redeem ~~Merger~~in ~~Sub,~~connection ~~pursuant~~with tothis ~~which~~Extraordinary ~~AIMA~~Meeting, ~~will~~your ~~complete~~redemption arequest ~~business~~tendered ~~combination~~in connection with the Docter ~~that involves~~Business aCombination ~~reincorporation~~will ~~merger~~still ~~and~~be ~~an acquisition merger~~processed.

~~This~~o ~~Current~~Any ~~Report~~public onshares ~~Form 8-K contains certain “forward-looking statements” within the meaning of the Securities Act and the Exchange Act. Statements that are~~ not ~~historical~~originally ~~facts,~~tendered ~~including~~for ~~statements about~~redemptions ~~the~~in ~~proposed~~connection ~~transactions~~with ~~described above, and~~ the ~~parties’~~Docter ~~perspectives~~Business ~~and~~Combination ~~expectations,~~will ~~are forward-looking statements. Such statements include, but are~~ not ~~limited~~be toredeemed, ~~statements regarding the proposed transactions, including the anticipated initial enterprise value~~ and ~~post-closing~~will ~~equity~~be ~~value,~~cancelled ~~the benefits of the proposed transaction, integration plans, expected synergies~~ and ~~revenue~~exchanged ~~opportunities, anticipated~~into ~~future~~such ~~financial~~PubCo ~~and~~Ordinary ~~operating~~Shares ~~performance~~as ~~and~~contemplated ~~results,~~under ~~including estimates for growth,~~ the ~~expected~~Business ~~management~~Combination ~~and governance of the combined company, and the expected timing of the proposed transactions~~Agreement. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

~~Such risks~~· ~~and~~If ~~uncertainties~~we ~~include,~~do ~~but are~~ not ~~limited~~consummate ~~to:~~the ~~(i)~~Docter ~~risks~~Business ~~related~~Combination prior to ~~the~~this ~~expected~~Extraordinary ~~timing~~Meeting and ~~likelihood~~do ofnot ~~completion~~hold of the ~~proposed~~ ~~business~~Extraordinary ~~combination,~~Meeting ~~including~~and ~~the~~implement ~~risk that~~ the ~~transaction~~Proposals ~~may~~on ~~not close due to one~~ or ~~more~~before ~~closing~~October ~~conditions to the transaction not being satisfied or waived~~28, ~~such as regulatory approvals not being obtained~~2025, onwe awill ~~timely~~(1) ~~basis~~cease orall ~~otherwise~~operations, orexcept ~~that a governmental entity prohibited, delayed or refused to grant approval~~ for the ~~consummation~~purpose of ~~the~~winding ~~transaction or required certain conditions, limitations or restrictions in connection with such approvals~~up; (ii2) ~~risks~~as ~~related~~promptly toas ~~the~~reasonably ~~ability~~possible ofbut ~~AIMA~~not ~~and~~more ~~Docter~~than toten ~~successfully~~business ~~integrate~~days ~~the businesses; (iii) the occurrence of any event~~thereafter, ~~change~~complete ~~or other circumstances that could give rise to~~ the ~~termination~~redemption of ~~the~~all ~~applicable transaction~~issued ~~agreements;~~and ~~(iv)~~outstanding ~~the~~public ~~risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of Docter or AIMA~~shares; (v3) ~~risks~~as ~~related~~promptly toas ~~disruption~~reasonably ofpossible ~~management~~following ~~time~~such ~~from~~redemption ~~ongoing~~and ~~business~~subject ~~operations due~~ to ~~the~~ ~~proposed transaction; (vi)~~ the ~~risk~~approval ~~that any announcements relating to the proposed transaction could have adverse effects on the market price~~ of AIMA’s ~~securities;~~remaining ~~(vii)~~shareholders ~~the~~after ~~risk~~such ~~that~~redemption ~~the proposed transaction~~ and ~~its announcement could have an adverse effect on~~ the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) risks relating to the health monitoring device industryBoard, ~~including~~liquidate ~~but not limited to governmental regulatory~~ and ~~enforcement changes~~dissolve, ~~market~~subject competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners. A further list and description of risks and uncertainties can be found in ~~the~~each ~~prospectus~~case ~~filed with the SEC on April 26, 2022 relating~~ to AIMA’s ~~initial~~obligations ~~public~~under ~~offering~~Cayman ~~(File~~Islands ~~No.~~law ~~333-263874), the~~to ~~annual~~provide ~~report of AIMA on Form 10-K~~ for ~~the~~claims ~~fiscal~~of ~~year~~creditors ~~ended on December 31, 2024, filed with the SEC on April 15, 2025 (the “Annual Report”),~~ and ~~in the final prospectus/proxy statement filed with the SEC on March 6, 2025 relating to the proposed transactions (File No. 333-284658) (the “Final Prospectus”), and~~ other ~~documents~~requirements ~~that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more~~ of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter and their subsidiaries or affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable ~~regulation~~law.

2 · If the Extraordinary Meeting is organized and the Proposals are implemented on or before October 28, 2025, irrespective of when or whether the Docter Business Combination is consummated:

~~Additional~~o ~~Information~~Any redemption request submitted in connection with this Extraordinary Meeting (including any redemption requests submitted after reversal/withdrawal of previous redemptions tendered in connection with the Docter Business Combination) will be effectuated and ~~Where~~executed tofollowing ~~Find~~the ItExtraordinary Meeting and adoption of the Charter Amendment.

Ino ~~connection~~Any ~~with~~redemption ~~the~~requests ~~proposed~~originally ~~transactions~~submitted ~~described~~in ~~herein,~~connection ~~Purchaser filed the Final Prospectus~~ with the ~~SEC~~Docter onBusiness ~~March~~Combination ~~6, 2025~~ and ~~AIMA~~not ~~held~~reversed anor ~~extraordinary~~withdrawn ~~general~~in ~~meeting~~connection onwith ~~March~~this ~~27,~~Extraordinary ~~2025~~Meeting ~~where the Business Combination was approved by holders of a requisite number of ordinary shares of AIMA. Shareholders~~ will ~~also~~remain beoutstanding, ~~able~~pending tothe ~~obtain~~consummation ~~a copy~~ of the ~~Final~~Docter ~~Prospectus~~Business ~~without charge from AIMA~~Combination. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, THE COMPANY AND THE PROPOSED TRANSACTIONS.

~~Participants~~o Any public shares not tendered for redemptions in ~~Solicitation~~connection with the Docter Business Combination or in connection with this Extraordinary Meeting will not be redeemed, and will be cancelled and exchanged into such PubCo Ordinary Shares if we complete the Docter Business Combination, or redeemed if we cannot complete a business combination timely and cease all operations.

~~AIMA,~~The ~~Docter,~~Company ~~and~~is ~~their~~working ~~respective~~with ~~directors,~~the ~~executive~~parties ~~officers,~~to ~~other members~~qualify offor ~~management,~~Nasdaq listing and ~~employees,~~cannot ~~under~~predict ~~SEC~~at ~~rules,~~this ~~may~~time bewhen ~~deemed~~it toexpects ~~be participants in~~ the ~~solicitation~~Docter ofBusiness ~~proxies~~Combination ofwill ~~AIMA’s shareholders~~be inconsummated, ~~connection~~if ~~with~~at ~~the proposed transactions described herein~~all. ~~Information~~The ~~regarding~~Company will announce the ~~persons~~proposed ~~who~~date ~~may,~~of ~~under~~closing ~~SEC rules, be deemed participants~~ in ~~the~~a ~~solicitation~~press ofrelease ~~AIMA’s~~at ~~shareholders~~least in2 ~~connection~~business ~~with~~days before the ~~proposed~~Docter ~~business~~Business ~~combination~~Combination iswill ~~set~~be ~~forth in the Final Prospectus~~consummated.

NoThe ~~Offer~~Company will extend the deadline for the Company’s public shareholders to deliver their redemption requests or ~~Solicitation~~reversals from Thursday, October 23, 2025, 5:00 p.m. Eastern Time to Monday, October 27, 2025, 11:00 a.m. Eastern Time.

~~This~~There ~~Current Report on Form 8-K~~ is ~~not~~no achange ~~proxy~~to ~~statement~~the ~~or solicitation of a proxy~~location, ~~consent~~the purpose or ~~authorization with respect to~~ any ~~securities or in respect~~ of the ~~proposed transactions described herein and shall~~proposals ~~not constitute an offer~~ to ~~sell~~be oracted aupon ~~solicitation~~at ~~of an offer to buy~~ the ~~securities~~Extraordinary ofMeeting. ~~AIMA~~The orphysical ~~Docter,~~location ~~nor shall there be any sale~~ of ~~any~~ ~~such~~the ~~securities~~Extraordinary inMeeting ~~any~~remains ~~state~~at ~~or jurisdiction in which such offer~~3F., ~~solicitation~~No. 25, ~~or sale would be unlawful prior to registration or~~Gongyuan ~~qualification~~Rd., ~~under~~Pingtung ~~the~~City, ~~securities~~Pingtung ~~laws~~County, ofTaiwan ~~such state or jurisdiction~~(R.O.C.), Noand ~~offering~~virtually ofvia ~~securities~~teleconference, ~~shall~~for bewhich ~~made~~you ~~except~~must byregister ~~means~~in ~~of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.~~advance at: https://forms.cloud.microsoft/r/pMLPzcu46r.

The Record Date for determining the Company shareholders entitled to receive notice of and to vote at the Meeting remains the close of business on September 29, 2025. Shareholders as of the Record Date who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Shareholders who have not yet done so are encouraged to vote as soon as possible.

If you have questions regarding the certification of your position or delivery of your shares, please contact:

Vstock Transfer LLC

18 Lafayette Place
Woodmere, NY 11598
Attn: Action Team

The Company’s shareholders who have questions regarding the Extraordinary Meeting or the impact on the votes casted, or would like to request documents may contact the Company’s proxy solicitor, Advantage Proxy, Inc., at (877) 870-8565, or banks and brokers can call (206) 870-8565, or by email at ksmith@advantageproxy.com.

Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the Adjournment, the date of the Extraordinary Meeting and the extension of the deadline to deliver a redemption request. These statements are based on current expectations on the date of this Current Report on Form 8-K and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

Additional Information and Where to Find It

On October 14, 2025, the Company filed the Proxy Statement with the SEC in connection with its solicitation of proxies for the Extraordinary Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the Proxy Statement (including any amendments or supplements thereto) and other documents filed with the SEC through the web site maintained by the SEC at www.sec.gov or contact proxy solicitor:

Advantage Proxy, Inc.
P.O. Box 10904
Yakima, WA 98909

Toll Free: (877) 870-8565

Collect: (206) 870-8565

Email: ksmith@advantageproxy.com

Participants in the Solicitation

The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Extraordinary Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the Proxy Statement. You may obtain free copies of these documents using the sources indicated above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 22, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit No.		Description
10.1		Termination Agreement, dated October 6, 2025, by and among Registrant, Inkrock and Seller
99.1		Securities Purchase Agreement, dated October 7, 2025, by and among Registrant, Inkrock and Seller
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aimfinity Investment Corp. I
Date: October 10, 2025	By:	/s/ I-Fa Chang
Date: October 22, 2025	By:	/s/ I-Fa Chang
	Name:	I-Fa Chang
	Title:	Chief Executive Officer

Filing Compare · Aimfinity Investment Corp. I